A Phase 1/2 interventional study of Durvalumab and Capivasertib in Triple Negative Breast Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 32 sites in 6 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing paclitaxel in Triple Negative Breast Neoplasms — 18 open to participants now, 29 under way, 4 of them phase 3. Paclitaxel · Triple Negative Breast Neoplasms.
Among the 63 studies testing paclitaxel in Triple Negative Breast Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 1/2, reaches primary completion later than 4 of the 28 other live ones, and was the 28th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →18 of the 63 studies testing paclitaxel in Triple Negative Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
UNICANCER · Sites in France, Spain
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 50 · Phase 3 8
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 55 across the 63 interventional studies. Of the 27 that completed or were terminated, 17 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 63 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
15 studies in Triple Negative Breast Neoplasms by AstraZeneca: 1 open now, 6 under way, 1 of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 1/2, and was the 9th registered.
AstraZeneca’s Triple Negative Breast Neoplasms studies by the year they started, since 2008.
10 of the studies testing paclitaxel in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03168880Phase 3Tata Memorial HospitalA Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer | 2026-11-30 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT06538896Zhejiang Cancer HospitalTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
| NCT04771871University College Hospital, IbadanMicroRNA Profiles in Triple Negative Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 63 studies testing paclitaxel in Triple Negative Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 15 in Triple Negative Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.
Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)
Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have positive tumor as determined by an IHC based assay
Exclusion criteria
Patients enrolled in Arm 2 only:
Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months
Patients enrolled in Arm 7 and 8 only: corneal disease in the opinion of the Investigator.
Patients enrolled in Arm 6, 7 and 8 only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
durvalumab + paclitaxel
Drug: Durvalumab · Drug: Paclitaxel
durvalumab + paclitaxel + capivasertib
Drug: Durvalumab · Drug: Capivasertib · Drug: Paclitaxel
durvalumab + paclitaxel + oleclumab
Drug: Durvalumab · Drug: Oleclumab · Drug: Paclitaxel
durvalumab + trastuzumab deruxtecan
Drug: Durvalumab · Drug: Trastuzumab deruxtecan
durvalumab + datopotamab deruxtecan
Drug: Durvalumab · Drug: Datopotamab deruxtecan
durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)
Drug: Durvalumab · Drug: Datopotamab deruxtecan
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Also known as: MEDI4736
Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
Also known as: AZD5363
Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
Also known as: MEDI9447
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Also known as: DS-8201a
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Also known as: Dato-DXd; DS-1062a
Dose Limiting Toxicity (DLT) Events
The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients
Time frame: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
Objective Response Rate (ORR)
Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.
Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Progression-free Survival (PFS)
Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)
Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Duration of Response (DoR)
Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date
Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Overall Survival (Count)
Number of patients with overall survival, the time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause
Time frame: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Overall Survival (Duration)
Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause
Time frame: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Progression-free Survival at 6 Months (PFS6)
Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\])
Time frame: 6 months following date of first dose
Data cut-off is 30Jun23 for Arms 1,2,5,6 and 29Nov24 for Arms 7-8
| Milestone | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Started | 23 | 31 | 33 | 58 | 62 | 33 |
| Completed | 0 | 0 | 0 | 0 | 6 | 3 |
| Not completed | 23 | 31 | 33 | 58 | 56 | 30 |
| Withdrew: Death | 14 | 17 | 25 | 22 | 28 | 3 |
| Withdrew: Ongoing study at time of data cut-off (30jun23 for arms 1-6 and 29nov24 for arms 7-8) | 8 | 9 | 5 | 33 | 24 | 25 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 3 | 2 | 3 | 2 |
| Withdrew: Reason unknown | 0 | 0 | 0 | 1 | 0 | 0 |
The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients
| Participants | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) Events | — | 0 | 0 | 0 | 0 | — |
Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.
| Percentage of patients | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 56.5 (34.5 to 76.8) | 54.8 (36.0 to 72.7) | 51.5 (33.5 to 69.2) | 62.1 (48.4 to 74.5) | 79.0 (66.8 to 88.3) | 81.8 (64.5 to 93.0) |
Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)
| Months | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 7.3 (5.4 to 11.3) | 6.4 (5.4 to 10.3) | 8.3 (4.8 to 9.3) | 12.6 (8.4 to 16.3) | 14.0 (11.0 to 21.1) | 11.2 (6.9 to 13.8) |
Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date
| Months | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Duration of Response (DoR) | 5.6 (3.75 to 26.12) | 7.9 (3.98 to 14.59) | 7.8 (5.42 to 17.77) | 15.2 (8.44 to NA) | 17.6 (10.51 to 27.27) | 11.5 (5.16 to NA) |
Number of patients with overall survival, the time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause
| Participants | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Died | 14 | 18 | 25 | 22 | 28 | 3 |
| Alive at data cut-off | 8 | 9 | 5 | 33 | 30 | 28 |
| Terminated prior to death | 1 | 4 | 3 | 3 | 4 | 2 |
Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause
| Months | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Overall Survival (Duration) | 30.0 (13.0 to NA) | 32.6 (12.9 to 40.0) | 24.8 (18.6 to 31.9) | 30.3 (18.8 to NA) | NA (23.2 to NA) | NA (NA to NA) |
Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\])
| Percentage of participants | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 |
|---|---|---|---|---|---|---|
| Progression-free Survival at 6 Months (PFS6) | 56.5 (34.3 to 73.8) | 52.4 (33.1 to 68.5) | 65.3 (46.0 to 79.1) | 75.2 (61.8 to 84.5) | 79.8 (67.2 to 88.0) | 78.2 (59.5 to 89.0) |
Collected over From the time of signature of informed consent up to 90 days after the last dose of study treatment. If an event starts post this period noted and is considered to be due to a late-onset toxicity to study drug, then it should be reported as an AE/SAE. Maximum duration of approximately 54 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durva + Pac | 14/23 (60.9%) | 1/23 (4.3%) | 22/23 (95.7%) |
| Durva + Pac + Capi 400mg Bid | 18/31 (58.1%) | 11/31 (35.5%) | 30/31 (96.8%) |
| Durva + Pac + Olec 3000mg | 25/33 (75.8%) | 4/33 (12.1%) | 32/33 (97%) |
| Durva + DS-8201a | 22/58 (37.9%) | 16/58 (27.6%) | 57/58 (98.3%) |
| Durva + Dato-DXd | 28/62 (45.2%) | 18/62 (29%) | 62/62 (100%) |
| Durva + Dato-DXd (PD-L1 High) | 3/33 (9.1%) | 5/33 (15.2%) | 33/33 (100%) |
| Event | Durva + Pac | Durva + Pac + Capi 400mg Bid | Durva + Pac + Olec 3000mg | Durva + DS-8201a | Durva + Dato-DXd | Durva + Dato-DXd (PD-L1 High) |
|---|---|---|---|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/23 | 0/31 | 0/33 | 5/58 | 0/62 | 0/33 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/23 | 2/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| PyrexiaGeneral disorders | 0/23 | 2/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| PneumoniaInfections and infestations | 0/23 | 0/31 | 0/33 | 2/58 | 4/62 | 0/33 |
| Pneumonia viralInfections and infestations | 1/23 | 0/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/23 | 0/31 | 0/33 | 2/58 | 0/62 | 1/33 |
| Covid-19Infections and infestations | 0/23 | 0/31 | 0/33 | 2/58 | 0/62 | 0/33 |
| Adrenal insufficiencyEndocrine disorders | 0/23 | 1/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/23 | 1/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| Cerebrovascular accidentNervous system disorders | 0/23 | 1/31 | 0/33 | 0/58 | 0/62 | 0/33 |
| Event | Durva + Pac | Durva + Pac + Capi 400mg Bid | Durva + Pac + Olec 3000mg | Durva + DS-8201a | Durva + Dato-DXd | Durva + Dato-DXd (PD-L1 High) |
|---|---|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 4/23 | 4/31 | 6/33 | 9/58 | 43/62 | 27/33 |
| NauseaGastrointestinal disorders | 11/23 | 8/31 | 11/33 | 46/58 | 42/62 | 18/33 |
| DiarrhoeaGastrointestinal disorders | 3/23 | 21/31 | 11/33 | 13/58 | 10/62 | 2/33 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/23 | 11/31 | 16/33 | 16/58 | 31/62 | 13/33 |
| RashSkin and subcutaneous tissue disorders | 9/23 | 18/31 | 9/33 | 7/58 | 21/62 | 13/33 |
| Peripheral sensory neuropathyNervous system disorders | 13/23 | 7/31 | 13/33 | 2/58 | 2/62 | 1/33 |
| FatigueGeneral disorders | 9/23 | 10/31 | 6/33 | 31/58 | 30/62 | 12/33 |
| ConstipationGastrointestinal disorders | 4/23 | 2/31 | 5/33 | 20/58 | 31/62 | 10/33 |
| HeadacheNervous system disorders | 2/23 | 5/31 | 12/33 | 9/58 | 9/62 | 3/33 |
| NeutropeniaBlood and lymphatic system disorders | 3/23 | 8/31 | 0/33 | 19/58 | 3/62 | 0/33 |
| Age, Continuous(Years) | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 | Total |
|---|---|---|---|---|---|---|---|
| Median | 52 (30 to 62) | 51 (32 to 71) | 54 (33 to 72) | 54 (29 to 81) | 53 (31 to 74) | 47 (29 to 74) | 52 (29 to 81) |
| Sex/Gender, Customized(Participants) | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 | Total |
|---|---|---|---|---|---|---|---|
| Female | 23 | 31 | 33 | 58 | 62 | 33 | 240 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 23 | 31 | 33 | 56 | 62 | 33 | 238 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm 1 | Arm 2 | Arm 5 | Arm 6 | Arm 7 | Arm 8 | Total |
|---|---|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 1 | 2 | 4 | 1 | 8 |
| Asian | 17 | 16 | 17 | 16 | 15 | 20 | 101 |
| White | 5 | 15 | 15 | 39 | 39 | 11 | 124 |
| Other | 1 | 0 | 0 | 1 | 4 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2018 to primary completion in Nov 2024, 71 months.
Results were first posted in Feb 2026, 1 year 2 months after primary completion.
Of 70 industry-sponsored phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 77. This study's 71 months is above that.
Counting every sponsor, half of 118 studies reached it within 56 months; a quarter within 43 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capivasertib · Paclitaxel · Trastuzumab deruxtecan · Datopotamab deruxtecan
Triple Negative Breast Neoplasms →